• Royal College of obstetricians and gynaecologists of great Britain Management of ovarian hyperstimulation syndrome

Royal College of obstetricians and gynaecologists of great Britain Management of ovarian hyperstimulation syndrome

HEALTH OF WOMAN.2016.7(113):66–72 
 

Royal College of obstetricians and gynaecologists of great Britain Management of ovarian hyperstimulation syndrome


Guide No. 5 (February 2016 Revision of the third manual 2006).

Abridged. Adapted By S. A. Shurpyak


REFERENCES

1. Braat DD, Schutte JM, Bernardus RE, Mooij TM, van Leeuwen FE. 2010. Maternal death related to IVF in the Netherlands 1984–2008. Hum Reprod 25:1782–6. http://dx.doi.org/10.1093/humrep/deq080; PMid:20488805

2. Whelan JG 3rd, Vlahos NF. 2000. The ovarian hyperstimulation syndrome. Fertil Steril 73:883–96. http://dx.doi.org/10.1016/S0015-0282(00)00491-X

3. Ata B, Tulandi T. 2009. Pathophysiology of ovarian hyperstimulation syndrome and strategies for its prevention and treatment. Expert Rev Obstet Gynecol. 4:299–311. http://dx.doi.org/10.1586/eog.09.10http://dx.doi.org/10.1586/eog.09.10

4. Mathur RS, Tan BK. 2014. British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. Hum Fertil (Camb). 17:257–68. http://dx.doi.org/10.3109/14647273.2014.961745; PMid:25380089

5. Evbuomwan IO, Davison JM, Murdoch AP. 2000. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox. Fertil Steril. 74:67–72. http://dx.doi.org/10.1016/S0015-0282(00)00573-2

6. Evbuomwan IO, Davison JM, Baylis PH, Murdoch AP. 2001. Altered osmotic thresholds for arginine vasopressin secre- tion and thirst during superovulation and in the ovarian hyperstimulation syndrome (OHSS): relevance to the pathophysiology of OHSS. Fertil Steril. 75:933–41. http://dx.doi.org/10.1016/S0015-0282(01)01704-6

7. Evbuomwan I. 2013. The role of osmoregulation in the pathophysiology and management of severe ovarian hyperstimulation syndrome. Hum Fertil (Camb). 16:162–7. http://dx.doi.org/10.3109/14647273.2013.831996; PMid:24047195

8. Zegers-Hochschild F, Mansour R, Ishihara O, Adamson GD, de Mouzon J, Nygren KG et al. 2014. International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2005. Fertil Steril. 101:366–78.e14. http://dx.doi.org/10.1016/j.fertnstert.2013.10.005; PMid:24188870

9. Delvigne A, Rozenberg S. 2002. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 8:559–77. http://dx.doi.org/10.1093/humupd/8.6.559; PMid:12498425

10. Kupka MS, Ferraretti AP, de Mouzon J, Erb K, D’Hooghe T, Castilla JA et al. 2014. European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology (ESHRE).Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Hum Reprod. 29:2099–113. http://dx.doi.org/10.1093/humrep/deu175; PMid:25069504

11. Kawwass JF, Kissin DM, Kulkarni AD, Creanga AA, Session DR, Callaghan WM et al. 2015. National ART Surveillance System (NASS) Group. Safety of assisted reproductive technology in the United States, 2000-2011. JAMA. 313:88–90. http://dx.doi.org/10.1001/jama.2014.14488; PMid:25562272

12. Sridev S, Barathan S. 2013. Case report on spontaneous ovarian hyperstimulation syndrome following natural conception associated with primary hypothyroidism. J Hum Reprod Sci. 6:158–61. http://dx.doi.org/10.4103/0974-1208.117164; PMid:24082659 PMCid:PMC3778607

13. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J et al. 2011. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update. 17:435. http://dx.doi.org/10.1093/humupd/dmr004; PMid:21646384

14. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. 2000. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 73:901–7. http://dx.doi.org/10.1016/S0015-0282(00)00492-1

15. Memarzadeh MT. 2010. A fatal case of ovarian hyperstimulation syndrome with perforated duodenal ulcer. Hum Reprod. 25:808–9. http://dx.doi.org/10.1093/humrep/dep434; PMid:20007616

16. Schenker JG, Weinstein D. 1978. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 30:255–68. http://dx.doi.org/10.1016/S0015-0282(16)43508-9

17. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. 1989. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 44:430–40. http://dx.doi.org/10.1097/00006254-198906000-00004; PMid:2660037

18. Navot D, Bergh PA, Laufer N. 1992. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 58:249–61. http://dx.doi.org/10.1016/S0015-0282(16)55188-7

19. Mathur R, Evbuomwan I, Jenkins J. 2005. Prevention and management of ovarian hyperstimulation syndrome. Curr Obstet Gynaecol. 15:132–8. http://dx.doi.org/10.1016/j.curobgyn.2005.01.003

20. Zosmer A, Katz Z, Lancet M, Konichezky S, Schwartz-Shoham Z. 1987. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril. 47:524–6. http://dx.doi.org/10.1016/S0015-0282(16)59069-4

21. Abramov Y, Elchalal U, Schenker JG. 1999. Pulmonary manifestations of severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril. 71:645–51. http://dx.doi.org/10.1016/S0015-0282(98)00399-9http://dx.doi.org/10.1016/S0015-0282(98)00528-7

22. Al Omari W, Ghazal-Aswad S, Sidky IH, Al Bassam MK. 2011. Ovarian salvage in bilaterally complicated severe ovarian hyperstimulation syndrome. Fertil Steril. 96:e77–9. http://dx.doi.org/10.1016/j.fertnstert.2011.06.005; PMid:21718996

23. Abramov Y, Elchalal U, Schenker JG. 1999. Severe OHSS: An ‘epidemic’ of severe OHSS: a price we have to pay? Hum Reprod. 14:2181–3. http://dx.doi.org/10.1093/humrep/14.9.2181

24. Human Fertilisation and Embryology Authority. http://www. hfea.gov.uk/docs/Latest_long_term_data_analysis_report_91-06.pdf.pdf. Accessed 2015, Oct 23.

25. Knight M, Kenyon S, Brocklehurst P, Neilson J, Shakespeare J, Kurinczuk JJ (Eds.). 2014. On behalf of MBRRACE-UK. Saving Lives, Improving Mothers’ Care: Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009–2012. Oxford: National Perinatal Epidemiology Unit. www.npeu. ox.ac.uk/mbrrace-uk/reports.

26. Human Fertilisation and Embryology Authority [http://www.hfea.gov.uk/ docs/General_Directions_0011_-_Reporting_adverse_ incidents_and_near_misses_V3.pdf]. Accessed 2015 Oct 23.

27. Royal College of Obstetricians and Gynaecologists. Ovarian hyperstimulation syndrome: what you need to know. London: RCOG. 2007. https://www.rcog.org.uk/ globalassets/documents/patients/patient-information-leaflets/gynaecology/ovarian-hyperstimulation-syndrome. pdf. Accessed 2015 Oct 23.

28. Balasch J, Carmona F, Llach J, Arroyo V, Jovй I, Vanrell JA. 1990. Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod. 5:348–51. PMid:2112558

29. Shrivastav P, Nadkarni P, Craft I. 1994. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod. 9:812–4. PMid:7929727

30. Lincoln SR, Opsahl MS, Blauer KL, Black SH, Schulman JD. 2002. Aggressive outpatient treatment of ovarian hyperstimu-lation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet. 19:159–63. http://dx.doi.org/10.1023/A:1014828027282; PMid:12036082 PMCid:PMC3455652

31. Smith LP, Hacker MR, Alper MM. 2009. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril. 92:1953–9. http://dx.doi.org/10.1016/j.fertnstert.2008.09.011; PMid:18976762

32. Shukla U, Deval B, Hamoda H, Savvas M, Narvekar N. 2011. A programme of outpatient surveillance for women at risk of severe OHSS following IVF: a prospective follow-up review of 99 cases. Hum Fertil (Camb). 14 Suppl 1:7.

33. Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. London: RCOG; 2015.

34. Lainas GT, Kolibianakis EM, Sfontouris IA, Zorzovilis IZ, Petsas GK, Tarlatzi TB et al. 2012. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol. 10:69. http://dx.doi.org/10.1186/1477-7827-10-69; PMid:22938051 PMCid:PMC3489837

35. Rollene NL, Amols MH, Hudson SB, Coddington CC. 2009. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril. 92:1169.e15–17. http://dx.doi.org/10.1016/j.fertnstert.2009.05.062; PMid:19608177

36. Baumgarten M, Polanski L, Campbell B, Raine-Fenning N. 2013. Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis. Hum Fertil (Camb). 16:168–74. http://dx.doi.org/10.3109/14647273.2013.833348; PMid:24047196

37. Nouri K, Tempfer CB, Lenart C, Windischbauer L, Walch K, Promberger R et al. 2014. Predictive factors for recovery time in patients suffering from severe OHSS. Reprod Biol 4–6. Endocrinol. 12:59.

38. Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 90;5:S188–93. 2008. http://dx.doi.org/10.1016/j.fertnstert.2008.08.034; PMid:19007627

39. Fabregues F, Balasch J, Manau D, Jimйnez W, Arroyo V, Creus M et al. 1998. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum Reprod. 13:2406–10. http://dx.doi.org/10.1093/humrep/13.9.2406; PMid:9806258

40. Nowicka MA, Fritz-Rdzanek A, Grzybowski W, Walecka I, Niemiec KT, Jakimiuk AJ. 2010. C-reactiveproteinastheindicator of severity in ovarian hyperstimulation syndrome. Gynecol Endocrinol. 26:399–403. http://dx.doi.org/10.3109/09513591003632266; PMid:20170348

41. Maslovitz S, Jaffa A, Eytan O, Wolman I, Many A, Lessing JB et al. 2004. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol. 104:321–6. http://dx.doi.org/10.1097/01.AOG.0000129956.97012.0d; PMid:15292006

42. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. 1992. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod. 7:180–3. PMid:1577929

43. Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takamizawa S et al. 2003. Treatment for ovarian hyperstimu- lation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol. 17:281–6. http://dx.doi.org/10.1080/713603291http://dx.doi.org/10.1080/gye.17.4.281.286; PMid:14503971

44. Delvigne A, Rozenberg S. 2003. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9:77–96. http://dx.doi.org/10.1093/humupd/dmg005; PMid:12638783

45. Raziel A, Friedler S, Schachter M, Strassburger D, Bukovsky I, Ron-El R. 1998. Transvaginal drainage of ascites as an alternative to abdominal paracentesis in patients with severe ovarian hyperstimulation syndrome, obesity, and generalized edema. Fertil Steril. 69:780–3. http://dx.doi.org/10.1016/S0015-0282(98)00003-X

46. Ozgun MT, Batukan C, Oner G, Uludag S, Aygen EM, Sahin Y. 2008. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol. 24:656–8. http://dx.doi.org/10.1080/09513590802342882; PMid:19031224

47. Royal College of Obstetricians and Gynaecologists. Management of Ascites in Ovarian Cancer Patients. Scientific Impact Paper No. 45. London: RCOG. 2014.

48. Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. 2010. The pathophysiology of ovarian hyper-stimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 94:1392–8. http://dx.doi.org/10.1016/j.fertnstert.2009.07.1662; PMid:19836016 PMCid:PMC3124341

49. Koike T, Araki S, Minakami H, Ogawa S, Sayama M, Shibahara H et al. 2000. Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome. Hum Reprod. 15:113–17. http://dx.doi.org/10.1093/humrep/15.1.113; PMid:10611198

50. Zhang Q, Xia L, Gao G. 2012. A new effective method in the treatment of severe ovarian hyperstimulation syndrome. Iran J Reprod Med. 10:589–94. PMid:25246931 PMCid:PMC4169854

51. Rova K, Passmark H, Lindqvist PG. 2012. Venous thrombo- embolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 97:95–100. http://dx.doi.org/10.1016/j.fertnstert.2011.10.038; PMid:22118992

52. ESHRE Capri Workshop Group.Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update 19:471–82. 2013. http://dx.doi.org/10.1093/humupd/dmt028; PMid:23825156

53. Gelbaya TA. 2010. Short and long-term risks to women who conceive through in vitro fertilization. Hum Fertil (Camb). 13:19–27. http://dx.doi.org/10.3109/14647270903437923; PMid:19929571

54. Gorkemli H, Camus M, Clasen K. 2002. Adnexal torsion after gonadotrophin ovulation induction for IVF or ICSI and its conservative treatment. Arch Gynecol Obstet.: 267. http://dx.doi.org/10.1007/s00404-001-0251-x

55. Cupisti S, Emran J, Mueller A, Dittrich R, Beckmann MW, Binder H. 2006. Course of ovarian hyperstimulation syndrome in 19 intact twin pregnancies after assisted reproduction techniques, with a case report of severe thromboem- bolism. Twin Res Hum Genet. 9:691–6. http://dx.doi.org/10.1375/twin.9.5.691; PMid:17032552

56. Amarin ZO. 2003. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. An aggressive, but perhaps life-saving procedure. Hum Reprod. 18:659–64. http://dx.doi.org/10.1093/humrep/deg116; PMid:12660253

57. Bellver J, Escudero E, Pellicer A. 2003. Bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome (OHSS): ovarian mutilating surgery is not an option in the management of severe OHSS. Hum Reprod. 18:1363–7. http://dx.doi.org/10.1093/humrep/deg285; PMid:12832357

58. Mathur RS, Jenkins JM. 2000. Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome? BJOG. 107:943–6. http://dx.doi.org/10.1111/j.1471-0528.2000.tb10393.x; PMid:10955422

59. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A et al. 2005. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod. 20:636–41. http://dx.doi.org/10.1093/humrep/deh638; PMid:15576388

60. Courbiere B, Oborski V, Braunstein D, Desparoir A, Noizet A, Gamerre M. 2011. Obstetric outcome of women with in vitro fertilization pregnancies hospitalized for ovarian hyperstimulation syndrome: a case-control study. Fertil Steril. 95:1629–32. http://dx.doi.org/10.1016/j.fertnstert.2010.12.015; PMid:21215968

61. Haas J, Yinon Y, Meridor K, Hershko-Klement A, Orvieto R, Schiff E et al. 2014. Is severe ovarian hyperstimulation syndrome associated with adverse pregnancy outcome? Evidence from a large case-control study. Am J Obstet Gynecol. 210;1:S329–30. http://dx.doi.org/10.1016/j.ajog.2013.10.707